Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis by De Crescenzo, Franco et al.
Cochrane Database of Systematic Reviews
Comparative efficacy and acceptability of pharmacological
treatments for insomnia in adults: a systematic review and
network meta-analysis (Protocol)
De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ,
Cipriani A, Barbui C, Amato L
De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L.
Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-anal-
ysis.
Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364.
DOI: 10.1002/14651858.CD012364.
www.cochranelibrary.com
Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and networkmeta-
analysis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
9ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iComparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-
analysis (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Comparative efficacy and acceptability of pharmacological
treatments for insomnia in adults: a systematic review and
network meta-analysis
Franco De Crescenzo1, Francesca Foti2,3, Marco Ciabattini4 , Cinzia Del Giovane5, Norio Watanabe6 , Monica Sañé Schepisi7, Digby
J Quested8, Andrea Cipriani9 , Corrado Barbui10 , Laura Amato11
1Institute of Psychiatry and Psychology, Catholic University of the Sacred Heart, Rome, Italy. 2Department of Psychology, “Sapienza”
University of Rome, Rome, Italy. 3IRCCS Santa Lucia Foundation, Rome, Italy. 4Public Health, Tor Vergata University, Rome, Italy.
5Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia,
Modena, Italy. 6Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of
Public Health, Kyoto, Japan. 7Clinical Epidemiology, National Institute for Infectious Diseases, IRCCS L. Spallanzani, Rome, 00149,
Italy. 8Department of Psychiatry and Mental Health, Oxford Health NHS Trust, Oxford, UK. 9Department of Psychiatry, University
of Oxford, Oxford, UK. 10Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona,
Italy. 11Department of Epidemiology, Lazio Regional Health Service, Rome, Italy
Contact address: Franco De Crescenzo, Institute of Psychiatry and Psychology, Catholic University of the SacredHeart, L.go A. Gemelli
8, Rome, 00168, Italy. decrescenzo.franco@gmail.com.
Editorial group: Cochrane Common Mental Disorders Group.
Publication status and date: Edited (no change to conclusions), published in Issue 9, 2016.
Citation: De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C,
Amato L. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network
meta-analysis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364. DOI: 10.1002/14651858.CD012364.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
1) To compare individual pharmacological treatments for insomnia in adults in terms of:
• efficacy, measured as self-rated quality of sleep or satisfaction with sleep; and
• acceptability of treatment.
2) To generate a clinically-useful hierarchy of available pharmacological treatments for insomnia in adults, according to their efficacy
and acceptability.
B A C K G R O U N D
Description of the condition
Insomnia is characterised by difficulty in initiating and maintain-
ing sleep, by early morning awakenings and by non-restorative
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sleep, which leads to a condition of daytime blunting. Sleep dis-
orders can lead to a reduction in cognitive, social-emotional, or
occupational functioning.
Typical symptoms of insomnia related to sleep (i.e. difficulty ini-
tiating sleep, difficulty maintaining sleep, early morning awaken-
ings, non-restorative sleep) are widespread, with an average point
prevalence affecting about a third of the population. The preva-
lence tends to fall to 10% to 15% of the population when con-
sidering daytime impairment, and the prevalence falls further to
a range of 6% to 10% if the main sets of diagnostic criteria are
considered (Ohayon 2002;Morin 2006; Ohayon 2009). Daytime
impairment is expressed in terms of the impact on daytime activ-
ities, in cognitive, social, and emotional domains (Léger 2010a).
Recent studies have shown that individuals with insomnia exhibit
impaired performance in several cognitive functions, including
working and episodic memory as well as some aspects of execu-
tive functioning (Fortier-Brochu 2012; Bonnet 2014; Shekleton
2014). Cognitive impairments have also been associated with hip-
pocampal atrophy (Joo 2014). Daytime impairments result in re-
duced productivity at work (Bolge 2009), reduced quality of life
(Léger 2012), an increased rate of accidents at work (Kessler 2012)
and increased economic burden (Léger 2010b; Rosekind 2010).
Indeed, insomnia has major public health implications, represent-
ing a significant burden to society. The cumulative expenditures
for insomnia include direct costs - such as outpatient encounters
and medical procedures, prescription and treatment costs, trans-
portation to and from treatments - and indirect costs - such as
healthcare utilisation, lost workplace productivity and increased
risk of accidents (Wickwire 2015). Several diseases are correlated
with insomnia, particularly hypertension and cardiovascular disor-
ders (Schwartz 1999; Vgontzas 2009a), type 2 diabetes (Vgontzas
2009b) and psychiatric disorders, such as depression and anxiety
disorders (Riemann 2007; Baglioni 2011).Drug and alcohol abuse
are also associated with insomnia (Johnson 2001; Shibley 2008).
To diagnose insomnia, the most commonly-used instruments
are the Diagnostic and Statistical Manual of Mental Disorders
(DSM IV-TR, DSM-5), the International Classification of Dis-
eases (ICD-10) and the International Classification of Sleep Dis-
orders (ICDS-2, ICSD-3). Together with disrupted sleep and day-
time impairment, the DSM-IV-TR sets a minimum duration of
one month to diagnose the condition, and the ICD-10 requires
symptom occurrence of at least 3 times a week for a month. In
addition, the ICD-10 requires the presence of marked personal
distress or interference with personal functioning. Both the ICDS-
3 and the DSM-5 establish a duration of at least three months,
with a disturbance frequency of at least 3 times per week despite
adequate conditions for sleep, and the absence of co-existing other
sleep disorders, mental disorders or medical conditions (WHO
1992; APA 2000; AASM 2005; APA 2013; AASM 2014).
Studies which have compared the main diagnostic systems have
shown that the diagnosis of insomnia obtained through their use
fails to adequately represent the actual extent of the disease in the
population (Ohayon 2009). In particular, it has been observed
that, in the same population, the diagnoses obtained by the ICD-
10 are very low in number compared to those obtained by the
DSM-IV-TR or the ICDS-2. Roth 2011 suggested that theDSM-
IV-TR was superior to other diagnostic systems. A recent study
showed that the prevalence of insomnia diagnoses is estimated to
have been reduced by half with the transition from DSM-IV-TR
toDSM-5 (Chung 2015). Some researchers identified themeasure
‘global sleep dissatisfaction’ - which considers duration, quality of
sleep, or both - as an important element which should be included
among diagnostic criteria to improve the accuracy and reliability
of the diagnosis (Ohayon 2009; Ohayon 2012).
Description of the intervention
Insomnia treatment is based on sleep hygiene, cognitive be-
havioural therapy for insomnia (CBT-I) and pharmacological
therapy (NICE 2014).
Sleep hygiene refers to a list of behavioural rules designed to in-
crease the likelihood of sleeping well. Poor sleep hygiene can con-
tribute to insomnia, but not cause it; for this reason sleep hygiene
education is a necessary, but not a sufficient, treatment for insom-
nia (Stepanski 2003).
CBT-I is a weekly psychological intervention, normally lasting
8 to 10 weeks. It consists of sleep hygiene instructions, stimulus
control therapy, sleep restriction therapy, relaxation and cognitive
therapy (Perlis 2005). CBT-I has been shown to be effective in
acute treatment as well as in long-term follow-up (Riemann 2009).
The combination of CBT-I and pharmacotherapy has been proved
to be more effective than CBT-I alone (Morin 2012). CBT-I is
often not easily accessible and the prescription of sleepmedications
is therefore increasing (Ford 2014).
Pharmacotherapy for insomnia consists of different types of drugs.
The most commonly-used drugs at present are benzodiazepine re-
ceptor agonists (BZRAs) (Ilyas 2012; Ford 2014), which are sub-
divided into benzodiazepines and benzodiazepine-like drugs (also
known as ‘Z-drugs’). Other drugs for treating insomnia include
antidepressants (mostly tricyclic antidepressants (TCAs)), mela-
toninergic drugs and orexin receptor antagonists.
BZRAs are positive allosteric modulators at the GABA-A recep-
tor. Gamma-aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter of the central nervous system and it is the physi-
ological ligand for GABA-A receptors, which are ligand-gated ion
channels. BZRAs’ action on the GABA-A receptor is self-limit-
ing, depending on the presence of GABA. In fact, in the absence
of GABA, BZRAs cannot open the chloride channel (Rudolph
2011). This self-limiting action is a main reason for the higher sa-
fety profile of BZRAs in comparison to previously-used drugs for
insomnia, such as barbiturates (Fischbach 1983). Benzodiazepines
bind non-selectively onto GABA-A receptors α1, α2, α3, or α5
subunits. Benzodiazepine-like drugs generally have a short half-
life, which grants few daytime adverse effects (Rudolph 2011).
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TCAs act as inhibitors of serotonin and norepinephrine reuptake
and they have also anticholinergic and antihistaminergic proper-
ties; it is supposed that the antihistaminergic action is the main
reason for their sedating properties (Richelson 1979; Ware 1983).
Melatoninergic drugs are divided into exogenous melatonin and
melatonin receptor agonists. Melatonin is an endogenous hor-
mone secreted by the pineal gland and involved in circadian
rhythms and the sleep/wake cycle. Exogenousmelatonin andmela-
tonin receptor agonists bind MT1 and MT2melatonin receptors,
which regulate the sleep-wake cycle and inhibit arousal signals
(Dubocovich 2005; Kato 2005).
Orexin receptor antagonists are a new class of drugs under devel-
opment. The orexins are excitatory neuropeptides, which convey
their actions on two G protein-coupled receptors called OX1 and
OX2. They are involved in the sleep/wake cycle, and it has been
demonstrated that individuals who suffer from narcolepsy show a
deficit of neurons producing orexins (Sakurai 2005).
How the intervention might work
BZRAs are a common choice for insomnia treatment and their use
has been systematically increasing over the years (Ford 2014). Ben-
zodiazepines are efficacious in terms of sleep onset latency (SOL)
and total sleep time (TST), and they are used clinically for differ-
ent types of insomnia: short-acting medications are indicated for
patients with SOL, while longer-acting medications are preferable
for patients with sleep maintenance insomnia (Holbrook 2000;
Buscemi 2007). Even though BZRAs have been shown to be effec-
tive in the acute treatment of insomnia, they cause important side
effects such as cognitive and motor impairments, and somnolence
(Holbrook 2000; Poyares 2004; Buscemi 2007;Wafford 2008). In
particular, long duration therapies with benzodiazepines may re-
sult in the appearance of dependency, withdrawal symptoms (e.g.
rebound insomnia) and worsening of sleep parameters (Allison
2003; Poyares 2004). Benzodiazepine-like drugs (i.e. eszopiclone;
zaleplon; zolpidem; zopiclone) have a short half-life, produce fewer
next-day cognitive and motor impairments (Wafford 2008; Nutt
2010), and at present their clinical use is preferred to benzodi-
azepines (Wafford 2008; Ford 2014).
Antidepressants are widely used for the treatment of insomnia,
and their prescription appears to increase over time together with
other non-benzodiazepine drugs (Ford 2014). However, among
antidepressants, only doxepin has been approved for the treatment
of insomnia and the prescription of other antidepressants (e.g. tra-
zodone, mirtazapine, amytriptiline) is off-label. Doxepin inhibits
serotonin and norepinephrine reuptake and inactivates choliner-
gic, histaminergic and alpha1-adrenergic receptors. At low dose
(less than 10mg/day), doxepin has little effect on the serotoner-
gic and adrenergic receptors, promoting sleep onset and duration,
and acting as a selective histamine H1 receptor antagonist (Yeung
2015). Therapeutic effects of doxepin are observed at very low
dosages (3mg to 6mg/day), improving sleep maintenance without
rebound insomnia or physical dependence (Hajak 2001). Com-
mon side effects include sedation, nasopharyngitis, gastrointesti-
nal effects, and hypertension (Weber 2010). Doxepin has also
been demonstrated to be effective for sleep maintenance and early
morning awakenings, which are the most common insomnia-re-
lated complaints in the elderly (Krystal 2010).
Melatonin receptor agonists, such as melatonin and ramelteon,
have been demonstrated to be a well-tolerated option for the treat-
ment of patients with insomnia characterised by difficulty in sleep
onset (Simpson 2008). Ramelteon was associated with reduced
subjective sleep latency and improved sleep quality, but not with
increased subjective total sleep time. Ramelteon was also associ-
ated with improvement in sleep efficiency, and total sleep time by
polysomnography, without significant side effects other than som-
nolence (Kuriyama 2014). At present, no study has demonstrated
clear effectiveness for melatoninergic drugs in insomnia.
There are many orexin receptor antagonists under investigation
for the treatment of insomnia, and they can be divided into single
orexin receptor antagonists (SORAs) and dual orexin receptor an-
tagonists (DORAs) (Equihua 2013). Thus far, the Food and Drug
Administration (FDA) has approved only suvorexant, which be-
longs to the DORAs category, for the treatment of insomnia. In a
recent double-blind, placebo-controlled trial, patients undergoing
suvorexant therapy showed improved subjective TST and subjec-
tive SOL compared with placebo. Those improvements were no-
ticeable after one week of treatment andweremaintained through-
out one year. The drug was well tolerated by insomnia patients
and the most commonly-reported adverse effects were daytime
somnolence and fatigue (Michelson 2014).
Other drugs approved for the treatment of insomnia are barbitu-
rates - chloral hydrate, ethchlorvynol, triclofos sodium - but they
are not used clinically any longer due to their important adverse
effects, toxic effects, and risk of misuse and dependence (Morin
2012; Mowry 2013).
Off-label drugs include antidepressants (with the exceptionof dox-
epin which has an indication for the treatment of insomnia) and
antipsychotics, which are used for the treatment of insomnia due
to psychiatric comorbidities and are considered as a second line
treatment (Morin 2012; Saddichha 2010). Antihistamines are still
found inmany over-the-counter (OTC) sleep aids (Risberg 1975).
Most OTCs are non-selective, having anti-muscarinic, anti-adren-
ergic properties and acting on dopamine and serotonin recep-
tors, which gives rise to unacceptable side effects. Indeed, antihis-
tamines used as sleep-inducing agents can cause drowsiness, but
the evidence for their efficacy is very limited and the data on safety
and tolerance now discourage their use in insomnia (Morin 2005;
Morin 2012; NICE 2014).
Why it is important to do this review
Previous pairwise meta-analyses could not generate clear hierar-
chies for the efficacy and acceptability of available treatments.
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Some Cochrane intervention reviews of sleep drugs for insom-
nia are in progress (Everitt 2013; Rösner 2013a; Rösner 2013b;
Rösner 2013c; Rösner 2013d; Moriichi 2014; Takeshima 2014),
while some non-Cochrane systematic reviews have been under-
taken (Holbrook 2000; Dündar 2004; Buscemi 2007; Winkler
2014), but this will be the first network meta-analysis in the field.
Our intention is to reduce the uncertainty about the efficacy of
treatments due to the limited number of direct comparisons as
reported in previous standard meta-analyses, and provide an evi-
dence-based hierarchy of the comparative efficacy and acceptabil-
ity of the drugs approved for the treatment of primary insom-
nia. This network meta-analysis will help clinicians, patients and
policy makers to make informed decisions on the best pharmaco-
logical treatments for insomnia. In conclusion, the present review
will synthesise the best available clinical evidence, including both
direct and indirect comparisons, in order to help clinicians and
patients to make informed decisions on the best pharmacological
treatments approved for insomnia in terms of efficacy and accept-
ability.
O B J E C T I V E S
1) To compare individual pharmacological treatments for insom-
nia in adults in terms of:
• efficacy, measured as self-rated quality of sleep or
satisfaction with sleep; and
• acceptability of treatment.
2) To generate a clinically-useful hierarchy of available pharmaco-
logical treatments for insomnia in adults, according to their effi-
cacy and acceptability.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) comparing
active drugs with other active drugs and/or placebo as oral therapy
in the treatment of primary insomnia. We will exclude controlled
clinical trials, cluster-randomised trials and cross-over trials, in
order to avoid possible sources of heterogeneity.
Types of participants
Participant characteristics
Adults aged 18 or older will be included. There will be no limits
in terms of gender or ethnicity.
Diagnosis
Insomnia diagnosed according to any standardised diagnostic cri-
teria, such as the DSM-III (APA 1980), DSM-III-R (APA 1987),
DSM-IV (APA 1994), DSM-IV TR (APA 2000), DSM-5 (APA
2013), ICD-10 (WHO 1992), International Classification of
Sleep Disorders (ICSD) (AASD 1990), ICSD-2 (AASM 2005) or
ICSD-3 (AASM 2014).
Co-morbidities
We will include studies on primary insomnia and exclude those
considering patients with insomnia due to psychiatric or physical
comorbidity. The distinction between primary and secondary in-
somnia is important for a networkmeta-analysis, because the sever-
ity and the pathophysiologic heterogeneity of the disturbances that
cause insomnia are likely to be strong confounders interfering with
the reliability of the results.Moreover, the diagnosis has important
implications for treatment: therapy for primary insomnia focuses
on the improvement of sleep, while therapy for secondary insom-
nia focuses on the causative medical problem, which also implies
that the dose and types of drugs may not be comparable.
Setting
We will consider studies performed in any setting.
Types of interventions
We will include RCTs that evaluate one or more of the follow-
ing pharmacological interventions as monotherapy, compared to
placebo and/or to another active agent:
• Antidepressants: amitriptyline; doxepin; mirtazapine;
trazodone;
• Benzodiazepines: brotizolam; clonazepam; diazepam;
estazolam; flunitrazepam; flurazepam; haloxazolam; loprazolam;
lorazepam; lormetazepam; midazolam; nimetazepam;
nitrazepam; quazepam; rilmazafone; temazepam; triazolam;
• Benzodiazepine-like agents: eszopiclone; zaleplon;
zolpidem; zopiclone;
• Melatoninergic drugs: melatonin; ramelteon;
• Orexin receptor antagonists: suvorexant.
We will exclude barbiturates, chloral hydrate, ethchlorvynol, tri-
clofos sodium and quetiapine due to their important adverse ef-
fects, toxic effects, and risk of misuse and dependence (Morin
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2012; Mowry 2013). We will also exclude herbal products and
medical devices.
Figure 1 shows the network of all possible pairwise comparisons
between the eligible treatments. We assume that any patient who
meets the inclusion criteria is, in principle, equally likely to be
randomised to any of the eligible treatments.
Figure 1. Figure 1 represents all possible pairwise comparisons from the network of the interventions.
Comparability of dosages
We will include only studies randomising patients to drugs
within the therapeutic dose. Both fixed-dose and flexible-
dose designs will be allowed. We will establish therapeu-
tic doses according to the British National Formulary (BNF)
(www.medicinescomplete.com). There is the possibility that some
trials may compare one agent at the upper limit of its therapeutic
range with another agent at the lower limit of its therapeutic range
within the same study. We may look at heterogeneity and then
add a binary variable (yes/no) to report if dosages are comparable
and use this information for analysis.
We will exclude: (i) combination treatments; (ii) augmentation
studies (e.g. drug A+ drug B versus drug A); (iii) all non-pharma-
cological treatments.
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Types of outcome measures
Studies that meet the above inclusion criteria will be included
regardless of whether they report on the following outcomes.
Primary outcomes
1. Quality of sleep or satisfaction with sleep index (as a
continuous outcome), as measured by any self-rated validated
scale, such as the Pittsburgh Sleep Quality Index (PSQI) (Buysse
1989), the Insomnia Severity Index (ISI) (Bastien 2001), or the
Leeds Sleep Evaluation Questionnaire (LSEQ) (Parrott 1978;
Zisapel 2003). In case other standardised scales were used by
some trials, we will use them in the absence of PSQI, ISI or
LSEQ.
2. Drop-outs for any reason.
Secondary outcomes
1. Drop-outs due to any adverse event.
2. Daytime functioning as measured by attentional tasks, tests
or any self-rated measure of function, for example the 36-item
short-form (SF-36) (Ware 1992), the Stanford Sleepiness Scale
(SSS) (Hoddes 1973) or the Epworth Sleepiness Scale (ESS)
(Johns 1991).
3. Sleep onset latency evaluated by polysomnography, defined
as the length of time (in minutes) after lights-out until sleep
onset.
4. Wake time after sleep onset (WASO) evaluated by
polysomnography, defined as the length of time (in minutes) of
wakefulness after the onset of persistent sleep.
5. Total sleep time (TST) evaluated by polysomnography,
defined as the total time (in minutes) a person spent sleeping
during the in-bed interval. TST is time in bed minus SOL and
minus WASO.
Timing of outcome assessment
We will consider outcomes assessed at four weeks post-treatment
or at its closest time point.Wewill include trials with an assessment
fromoneweekup to threemonths. Separately, wewill also consider
long-term outcomes (more than 3 months).
Hierarchy of outcome measures
For the primary outcome “Quality of sleep” we will select first the
PSQI scale firstly, second the ISI scale and third the LSEQ scale.
Measures of daytime functioning will be considered and analysed
separately.
Search methods for identification of studies
Electronic searches
1. Bibliographic databases
We will search the following bibliographic databases for reports
of RCTs using relevant subject headings (controlled vocabularies)
and search syntax, appropriate to each resource (Appendix 1):
• Cochrane Central Register of Controlled Trials
(CENTRAL, all years)
• Ovid MEDLINE (1950 onwards)
• PubMed (current year)
• Ovid Embase (1980 onwards)
• Ovid PsycINFO (all years)
We will not restrict our search by language, date or publication
status.
We will conduct a separate search to identify other systematic
reviews and meta-analyses (on Ovid MEDLINE; the Cochrane
Database of Systematic Reviews (CDSR); the Database of Ab-
stracts of Reviews of Effects (DARE); and Epistemonikos)
2. International trial registries
We will search the World Health Organization’s trials portal (
ICTRP) andClinicalTrials.gov to identify unpublished or ongoing
studies.
Searching other resources
Reference lists
Wewill screen the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches (for example unpublished or in-press
citations).
Correspondence
We will contact trialists and subject experts for information on
unpublished or ongoing studies or to request additional trial data.
Data collection and analysis
Selection of studies
Two review authors (FDC, MC) will independently screen titles
and abstracts retrieved by the search strategy. Full-texts of poten-
tially relevant studies will then be assessed independently by two
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authors (FDC, MC). Disagreements will be resolved through dis-
cussion with a third member of the review team (LA).
Data extraction and management
We will use a data collection form to extract study characteristics
and outcome data, which has been piloted on at least one study
in the review. Two review authors (FDC, MC) will independently
extract study characteristics and outcome data from included stud-
ies, as follows:
Methods: first author or acronym, year of publication, publi-
cation (full-text publication, abstract publication, unpublished
data), study design.
Participants: diagnosis, sample size (N), mean age, gender distri-
bution, severity of illness, treatment setting.
Interventions: number of patients allocated to each arm, drug
name, dose, route or administration, duration of the interventions
and follow-up.
Outcomes: primary and secondary outcomes evaluated.
Adverse events (AEs): AEs as unfavourable symptoms occurring
during the course of the study.
Notes: country, funding source; investigational drug versus com-
parator.
We will note in the ’Characteristics of included studies’ table if
outcome data were not reported in a usable way. We will resolve
disagreements by consensus or by involving a third person (LA).
Two review authors (FDC, MC) will enter data into ReviewMan-
ager (RevMan 2014). We will double-check that data are entered
correctly by comparing the data presented in the systematic review
with the study reports.
Data on potential effect modifiers
We will extract from each included study data that may act as
effect modifiers: age, funding source, studies reported as high risk
of bias.
Outcome data
We will extract from each included study:
• self-rated quality of sleep scale, as a continuous outcome:
mean and standard deviation (SD);
• drop-outs for any reason: number of participants who
dropped out for any reason, of the total number of participants
randomised to each arm;
• drop-outs due to any adverse events: number of participants
who dropped out because of any adverse event, of the total
number of participants randomised to each arm;
• daytime functioning; each single scale will be analysed
separately as a continuous outcome: mean and SD;
• polysomnographic outcomes SOL, WASO and TST: mean
in minutes and SD.
Assessment of risk of bias in included studies
Two review authors (FDC, MC) will independently assess the risk
of bias of each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involv-
ing another author (LA). The following domains will be assessed:
random sequence generation, allocation concealment, blinding of
providers and participants, blinding of outcome assessment, in-
complete outcome data, and selective outcome reporting. We will
judge each potential source of bias as high, low or unclear and
provide a supporting quotation from the study report together
with a justification for our judgment in the ’Risk of bias’ table.
We will report the ’Risk of bias’ judgements across different stud-
ies for each of the domains listed. Where information on risk of
bias relates to unpublished data or correspondence with a trialist,
we will note this in the ’Risk of bias’ table. A judgement of high
risk of bias in one or more domain will be considered as a ‘high
risk’ study, a judgement of low risk of bias in all domains will be
considered as a ‘low risk’ study, and a judgement of unclear risk
of bias in one or more domains as an ‘unclear risk’ study. When
considering treatment effects, we will take into account the risk of
bias for the studies that contribute to that outcome.
Measures of treatment effect
Relative treatment effects
Dichotomous data
Dichotomous outcomes will be analysed by calculating the relative
risk (RR) for each trial with the uncertainty in each result being
expressed by its 95% confidence interval (CI).
Continuous data
Continuous outcomes will be analysed by calculating the mean
difference (MD) with the relative 95% CI when the study used
the same instruments for assessing the outcome. We will use the
standardised mean difference (SMD) when studies used different
instruments.
Relative treatment ranking
For any primary outcome we will also estimate the ranking prob-
abilities for all treatments of being at each possible rank for each
intervention. Then we will obtain a treatment hierarchy using the
surface under the cumulative ranking curve (SUCRA) and mean
ranks. SUCRA will be expressed as a percentage and is interpreted
as the percentage of efficacy or safety a treatment achieves in rela-
tion to a treatment that would be ranked first without uncertainty
(Salanti 2011).
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Unit of analysis issues
For simple pairwise meta-analysis, if all arms in a multi-arm trial
are to be included in the meta-analysis and one treatment arm is
to be included in more than one treatment comparison, then we
will divide the number of events and the number of participants
in that arm by the number of treatment comparisons made. This
method will avoid the multiple use of participants in the pooled
estimate of treatment effect, while retaining information fromeach
arm of the trial. It will, however, compromise the precision of the
pooled estimate slightly. In the network meta-analysis, we account
for the correlation between the effect sizes from multi-arm studies
(Higgins 2011, chapter 16.5.4).
Dealing with missing data
We will contact study authors when there are missing or unclear
data. If dichotomous outcome data are still missing, they will be
managed according to the intention-to-treat (ITT) principle, and
we will assume that patients who dropped out after randomisation
had a negative outcome. Missing continuous outcome data will
either be analysed using the last observation carried forward to
the final assessment (LOCF) or, if LOCF data are reported by the
trial authors, will be analysed on an endpoint basis, including only
participants with a final assessment. When P values, t-values, CIs
or standard errors are reported in articles, we will calculate SDs
from their values (Furukawa 2006).
Assessment of heterogeneity
In the context of the network meta-analysis, we will assume a
common within-network heterogeneity and the generalised Q-
statistic estimator will be used for the heterogeneity variance.
Assessment of clinical and methodological heterogeneity
within treatment comparisons
To evaluate the presence of heterogeneity deriving from different
trial designs or different clinical characteristics of study partici-
pants, we will generate descriptive statistics for trial and study pop-
ulation characteristics across all eligible trials that compare each
pair of interventions. We will assess the presence of clinical het-
erogeneity within each pairwise comparison by comparing these
characteristics.
Assessment of transitivity across treatment comparisons
We expect that the transitivity assumption will hold assuming that
all pairwise comparisons do not differ on average with respect to
the distribution of effect modifiers (e.g. age). The assumption of
transitivity will be evaluated in each primary outcome by compar-
ing the clinical andmethodological characteristics (potential effect
modifiers presented in Data extraction and management) across
the different pairwise comparisons.
Assessment of reporting biases
The possibility of reporting bias will be evaluated for each pri-
mary outcome by means of the contour-enhanced funnel plots
if enough studies (at least 10) are available (Peters 2008). These
are funnel plots showing areas of statistical significance and they
can help to distinguish publication bias from other possible rea-
sons for asymmetry. In a network of interventions each study es-
timates the relative effect of different interventions, so asymme-
try in the funnel plot cannot be judged. To account for this, we
will use an adaptation of the funnel plot by subtracting from each
study-specific effect size the mean of meta-analysis of the study-
specific comparison and plot it against the study’s standard error
(Chaimani 2012; Chaimani 2013).We will draw the comparison-
adjusted funnel plot for all placebo-controlled trials (if at least 10
trials are available). Any asymmetry in the plot indicates the pres-
ence of small study effects and not necessarily reporting bias.
Data synthesis
Methods for direct treatment comparisons
We will perform conventional pairwise meta-analyses for pri-
mary and secondary outcomes using a random-effects model in
RevMan for every treatment comparison with at least two studies
(DerSimonian 1986).
Methods for indirect and mixed comparisons
We will perform network meta-analysis (NMA) for primary out-
comes. NMA is a method of synthesising information from a net-
work of trials addressing the same question but involving different
interventions (Cipriani 2013). NMA combines direct evidence
(from studies comparing two treatments, e.g. A versus B) and in-
direct evidence (e.g. the comparison A versus B comes from stud-
ies comparing A and B versus a common comparator C) across a
network of randomised trials into a single effect size, and under
certain assumptions it can increase the precision in the estimates
while randomisation is respected. We will perform NMA using a
random-effects model within a frequentist setting assuming equal
heterogeneity across all comparisons, and we will account for cor-
relations induced by multi-arm studies (Lu 2006; Salanti 2009).
The models will enable us to estimate the probability of each in-
tervention being the best for each outcome, given the relative ef-
fect sizes as estimated in NMA. We will perform NMA in Stata
13 using the ’mvmeta’ command and self-programmed Stata rou-
tines available at http://www.mtm.uoi.gr (Chaimani 2014;White
2011; White 2012).
Results ofmeta-analysis andNMAwill be appliedwhen reasonable
and presented as summary relative effect sizes (MD, SMD or RR)
for each possible pair of treatments.
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Subgroup analysis and investigation of heterogeneity
Measures and tests for heterogeneity
We will statistically assess the presence of heterogeneity for all di-
rect pairwise comparisons using the τ 2. The assessment of sta-
tistical heterogeneity in the entire network will be based on the
magnitude of the heterogeneity variance parameter (τ 2) estimated
from the NMA models. We will compare the magnitude of the
heterogeneity variance with the empirical distribution as derived
by Turner (Turner 2012). We will also estimate a total I2 value
for heterogeneity in the network as described elsewhere (Jackson
2014).
Assessment of statistical inconsistency
Consistency in a network of treatments refers to the agreement
between direct and indirect evidence on the same comparisons.
Joint analysis can be misleading if the network is substantially in-
consistent. Inconsistency can be present if the trials in the network
have very different protocols and their inclusion/exclusion crite-
ria are not comparable or may result as an uneven distribution of
the effect modifiers across groups of trials that compare different
treatments.
Local approaches for evaluating inconsistency
We will first check for any erroneous data abstraction. Then, to
evaluate the presence of inconsistency locally, we will use the loop-
specific approach. This method evaluates the consistency assump-
tion in each closed loop of the network separately as the difference
between direct and indirect estimates for a specific comparison in
the loop (inconsistency factor) (Veroniki 2013). The magnitude
of the inconsistency factors and their 95% CIs can then be used
to infer as to the presence of inconsistency in each loop. We will
assume a common heterogeneity estimate within each loop. We
will present the results of this approach graphically in a forest plot
using the ’ifplot’ command in Stata (Chaimani 2013).
Investigation of heterogeneity and inconsistency
If sufficient studies are available, we will perform network sub-
group analyses for the primary efficacy outcome by using age (over
65 years old versus 18 to 65 years old) as possible sources of incon-
sistency or heterogeneity (Floyd2000;Ohayon2002; Ancoli-Israel
2008; Fetveit 2009).
Sensitivity analysis
If enough studies per comparison are identified, we will carry out
a sensitivity analysis of the primary outcomes including only trials
at low risk of bias in all domains. Moreover, we will perform a
sensitivity analysis to assess the robustness of the results if impu-
tations have been applied.
’Summary of findings’ table
The main results of the review will be presented in ’Sum-
mary of findings’ (SoF) tables, as recommended by Cochrane
(Schünemann 2011).We will produce the SoF tables for estimates
from the NMA based on the methodology developed from the
GRADE Working Group (GRADE 2004). For more details, see
Salanti 2014. We will include an overall grading of the evidence
for the following main outcomes:
Efficacy:
• Self-rated quality of sleep or satisfaction with sleep.
Acceptability:
• Drop-outs for any reason.
Wewill grade quality of the evidence considering study limitations,
indirectness, inconsistency, imprecision of effect estimates, and
risk of publication bias. According to the software GRADEpro
GDT 2014, we will assign four levels of quality of evidence: high,
moderate, low, very low.
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Library
Databases on the Cochrane Library (CDSR, CENTRAL, DARE, HTA and NHS-EED) will be searched using the following strategy
(note specific list of drug terms):
#1 insomni*:ti
#2 MeSH descriptor: [Sleep Initiation and Maintenance Disorders] explode all trees and with qualifier(s): [Drug therapy - DT]
#3 insomni*
#4 sleep near/2 disorder*
#5 MeSH descriptor: [Sleep Disorders] explode all trees and with qualifier(s): [Drug therapy - DT]
#6 MeSH descriptor: [Sleep Initiation and Maintenance Disorders] explode all trees
#7 (#3 or #4 or #5 or #6)
#8 (amitriptyline or doxepin or mirtazapine or trazodone)
#9 (benzodiaz* or brotizolam or clonazepam or diazepam or estazolam or flunitrazepam or flurazepam or haloxazolam or loprazolam
or lorazepam or lormetazepam or midazolam or nimetazepam or nitrazepam or oxazepam or quazepam or rilmazafone or temazepam
or triazolam)
#10 (nonbenzodiazepin* or non-benzodiazepin* or “Z drug*” or eszopiclon* or zaleplon or zolpidem or zopiclon*)
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#11 (melatonin* or ramelteon)
#12 (orexin or suvorexant)
#13 (#8 or #9 or #10 or #11 or #12)
#14 (#7 and #13)
#15 (pharmacotherap* or antidepress* or anti depress* or benzodiazepin* or melaton*):ti
#16 MeSH descriptor: [Antidepressive Agents] explode all trees and with qualifier(s): [Administration & dosage - AD, Therapeutic use
- TU]
#17 MeSH descriptor: [Benzodiazepines] explode all trees and with qualifier(s): [Administration & dosage - AD, Therapeutic use -
TU]
#18 MeSH descriptor: [Hypnotics and Sedatives] explode all trees and with qualifier(s): [Administration & dosage - AD, Therapeutic
use - TU]
#19 (#15 or #16 or #17 or #18)
#20 (#1 or #6) and #19
#21 (#2 or #14 or #20)
OVID databases
Search strategies for MEDLINE, Embase and PsycINFO have been designed to reduce the identification of a large number of irrelevant
hits, e.g. treatment studies for depression or other common mental disorders where the symptoms of insomnia are discussed in terms
of association, risk or as an adverse effect of psychotropic medication. The searches have also been tailored to exploit the nature and
scope of each biomedical database.
We will search OVID MEDLINE (1946 onwards) using the following combination of terms:
1. insomni*.ti,kf.
2. “Sleep Initiation and Maintenance Disorders”/dt [Drug Therapy]
3. Sleep Wake Disorders/dt [Drug Therapy, Therapy]
4. Sleep/dt,th [Drug Therapy]
5. insomni*.ti,ab,kf.
6. (sleep adj2 disorder*).ti,ab,kf.
7. exp “Sleep Initiation and Maintenance Disorders”/
8. (Pittsburgh SleepQuality Index or PSQI or Insomnia Severity Index or Leeds Sleep Evaluation Questionnaire or LSEQ or (insomnia
adj2 (evaluation or index or measure* or questionnaire or rating or scale or schedule or subscale))).ab.
9. or/5-8
10. (amitriptyline or doxepin or mirtazapine or trazodone).mp.
11. (benzodiaz* or brotizolam or clonazepam or diazepam or estazolam or flunitrazepam or flurazepam or haloxazolam or loprazolam
or lorazepam or lormetazepam or midazolam or nimetazepam or nitrazepam or oxazepam or quazepam or rilmazafone or temazepam
or triazolam).ti,ab,kf,rn,nm.
12. (nonbenzodiazepin* or non-benzodiazepin* or “Z drug*” or eszopiclon* or zaleplon or zolpidem or zopiclon*).mp.
13. (melatonin* or ramelteon).mp.
14. (orexin or suvorexant).mp.
15. or/10-14
16. 9 and 15
17. benzodiazepines/ad,tu or clonazepam/ad,tu or diazepam/ad,tu or flunitrazepam/ad,tu or flurazepam/ad,tu or lorazepam/ad,tu or
nitrazepam/ad,tu or temazepam/ad,tu or estazolam/ad,tu or midazolam/ad,tu or triazolam/ad,tu
18. exp Antidepressive Agents/ad,tu,th [Administration & Dosage, Therapeutic Use, Therapy]
19. “Hypnotics and Sedatives”/ad,tu,th [Administration & Dosage, Therapeutic Use, Therapy]
20. (pharmacotherap* or antidepress* or anti depress* or benzodiazepin* or melaton*).ti,kf.
21. or/17-20
22. (1 or 7) and 21
23. controlled clinical trial.pt.
24. randomized controlled trial.pt.
25. (randomi#ed or randomi#ation).ab,ti.
26. randomly.ab.
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27. (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or
number* or place* or recruit* or subsitut* or treat*)).ab.
28. placebo*.ab,ti.
29. trial.ab,ti.
30. groups.ab.
31. ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp.
32. exp animals/ not (humans.sh. and exp animals/)
33. or/23-31
34. 33 not 32
35. (2 or 3 or 4 or 16 or 22) and 34
OVID Embase will be searched (1980 onwards) using the following combination of terms:
1. *insomnia/
2. insomnia/dt
3. sleep disorder/dt
4. insomni*.ti,kw.
5. exp insomnia/
6. Insomnia Severity Index/
7. insomni*.ti,ab,kw.
8. (Pittsburgh SleepQuality Index or PSQI or Insomnia Severity Index or Leeds Sleep Evaluation Questionnaire or LSEQ or (insomnia
adj2 (evaluation or index or measure* or questionnaire or rating or scale or schedule or subscale))).ab.
9. or/5-8
10. (amitriptyline or doxepin or mirtazapine or trazodone).mp.
11. (benzodiaz* or brotizolam or clonazepam or diazepam or estazolam or flunitrazepam or flurazepam or haloxazolam or loprazolam
or lorazepam or lormetazepam or midazolam or nimetazepam or nitrazepam or oxazepam or quazepam or rilmazafone or temazepam
or triazolam).ti,ab,kw,rn.
12. brotizolam/ or clonazepam/dt or diazepam/dt or estazolam/ or flunitrazepam/dt or flurazepam/dt or haloxazolam/ or loprazolam/
or lorazepam/dt or lormetazepam/ or midazolam/dt or nimetazepam/ or quazepam/ or rilmazafone/ or temazepam/ or triazolam/dt
13. *clonazepam/ or *diazepam/ or *flunitrazepam/ or *flurazepam/ or *lorazepam/ or *midazolam/ or *temazepam/ or *triazolam/
14. (nonbenzodiazepin* or non-benzodiazepin* or “Z drug*” or eszopiclon* or zaleplon or zolpidem or zopiclon*).mp.
15. eszopiclone/dt or zopiclone/dt or zolpidem/dt or zolpidem tartrate/dt or zaleplon/dt
16. *eszopiclone/ or *zopiclone/ or *zolpidem/ or *zolpidem tartrate/ or *zaleplon/
17. (melatonin* or ramelteon).mp.
18. (orexin or suvorexant).mp.
19. or/10-18
20. randomized controlled trial.de.
21. randomization.de.
22. placebo.de.
23. placebo$.ti,ab.
24. randomi#ed.ti,ab.
25. randomly.ab.
26. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp.
27. ((animal or nonhuman) not (human and (animal or nonhuman))).de.
28. or/20-26
29. 28 not 27
30. 9 and 19 and 29
31. limit 30 to exclude medline journals
32. (1 or 2 or 3 or 4) and 19 and 29
33. 33 or 34
OVID PsycINFO will be searched (all years) using the following combination of terms:
1. insomnia/
2. insomni*.ti,ab,id.
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3. (Pittsburgh Sleep Quality Index or PSQI or Insomnia Severity Index or ISI or Leeds Sleep Evaluation Questionnaire or LSEQ or
(insomnia adj2 (evaluation or index or measure* or questionnaire or rating or scale or schedule or subscale))).tm.
4. or/1-3
5. sleep disorders/
6. (insomni* or (sleep adj2 disorder*)).ti,id.
7. “3340”.cc. [Classification Code=Clinical Psychopharmacology]
8. ((1 or 5 or 6) and 7)
9. (amitriptyline or doxepin or mirtazapine or trazodone).ti,ab,id,sh.
10. (benzodiaz* or brotizolam or clonazepam or diazepam or estazolam or flunitrazepam or flurazepam or haloxazolam or loprazolam
or lorazepam or lormetazepam or midazolam or nimetazepam or nitrazepam or oxazepam or quazepam or rilmazafone or temazepam
or triazolam).ti,ab,id,sh.
11. (nonbenzodiazepin* or non-benzodiazepin* or “Z drug*” or eszopiclon* or zaleplon or zolpidem or zopiclon*).ti,ab,id,sh.
12. (melatonin* or ramelteon).ti,ab,id,sh.
13. (orexin or suvorexant).ti,ab,id,sh.
14. or/9-13
15. (pharmacotherap* or antidepress* or anti depress* or benzodiazepin* or melaton*).ti.
16. exp antidepressant drugs/
17. exp benzodiazepines/
18. exp hypnotic drugs/
19. drug therapy/
20. or/15-19
21. treatment effectiveness evaluation.sh.
22. clinical trials.sh.
23. placebo.sh.
24. placebo.ti,ab,id.
25. randomly.ab.
26. randomi#ed.ti,ab,id.
27. (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or
number* or place* or recruit* or subsitut* or treat*)).ab.
28. trial.ti,ab,id.
29. ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask* or dummy)).ti,ab,id.
30. (control* adj3 group*).ab.
31. “2000”.md. [Methodology=Treatment Outcome/Clinical Trial]
32. or/21-31
33. (4 and 14 and 32)
34. (8 and 32)
35. (6 and 20 and 32)
36. or/33-35
PubMed will be searched (current year only) using the following terms:
((insomni* OR sleep disorder* OR sleep wake disorder* OR sleep initiation OR sleep onset OR sleep latency) AND (amitriptyline
OR doxepin OR mirtazapine OR trazodone OR benzodiazepin* OR brotizolam OR clonazepam OR diazepam OR estazolam OR
flunitrazepam OR flurazepam OR haloxazolam OR loprazolam OR lorazepam OR lormetazepam OR midazolam OR nimetazepam
OR nitrazepam OR oxazepam OR quazepam OR rilmazafone OR temazepam OR triazolam OR nonbenzodiazepin* OR non-
benzodiazepin* OR “Z drug” OR “Z drugs” OR eszopiclon* OR zaleplon OR zolpidem OR zopiclon* OR melatonin* or ramelteon
OR orexin OR suvorexant) AND (random* OR placebo OR trial OR (control* AND group) OR treat*[Title] OR efficacy[Title] OR
effectiveness[Title)) Filters: Publication date from 2015/01/01 to 2016/01/31
International Trial Registries:
The World Health Organisations trials portal (ICTRP) will be searched using the following search string:
(insomnia and amitriptyline or insomnia and doxepin or insomnia andmirtazapine or insomnia and trazodone or insomnia and brotizolam or
insomnia and clonazepam or insomnia and diazepam or insomnia and estazolam or insomnia and flunitrazepam or insomnia and flurazepam
or insomnia and haloxazolam or insomnia and loprazolam or insomnia and lorazepam or insomnia and lormetazepam or insomnia and
midazolam or insomnia and nimetazepam or insomnia and nitrazepam or insomnia and quazepam or insomnia and rilmazafone or insomnia
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and temazepam or insomnia and triazolam or insomnia and eszopiclone or insomnia and zaleplon or insomnia and zolpidem or insomnia
and zopiclone or insomnia and melatonin or insomnia and ramelteon or insomnia and orexin or insomnia and suvorexant)
An advanced search of ClinicalTrials.gov will be conducted, for:
CONDITION=insomnia and STUDY TYPE=interventional
Results will be imported into Excel and filtered by INTERVENTION=drug and STUDY DESIGNS=randomized
WH A T ’ S N E W
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